| 英語名 | 研究コード | 研究開発ステージ | 会社 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|
| Bosakitug | BSI-045B; TQC-2731; TQC2731 | Phase 3 Clinical | Biosion Inc | Nasal Polyps; Sinusitis; Asthma; Pulmonary Disease, Chronic Obstructive; Dermatitis, Atopic | 詳細 |
| Ecleralimab | CSJ-117; NOV-14 | Phase 2 Clinical | Novartis Pharma Ag | Asthma; Pulmonary Disease, Chronic Obstructive | 詳細 |
| WIN-1001X | WIN-1001X | Phase 2 Clinical | Whanin Pharmaceutical Co Ltd | Nerve Degeneration; Parkinson Disease | 詳細 |
| PF-07275315 | PF-07275315 | Phase 2 Clinical | Pfizer Inc | Dermatitis, Atopic | 詳細 |
| Lunsekimig | SAR-443765 | Phase 2 Clinical | Sanofi | Nasal Polyps; Asthma; Sinusitis; Inflammation | 詳細 |
| AZD-8630 | AZD-8630; AMG-104 | Phase 2 Clinical | Astrazeneca Plc, Amgen Inc | Asthma | 詳細 |
| SHR-1905 | SHR-1905; AIO-001 | Phase 2 Clinical | Nasal Polyps; Respiratory Tract Diseases; Sinusitis; Asthma; Pulmonary Disease, Chronic Obstructive | 詳細 | |
| CM-326(Connaught Biomedical Technology) | CM-326 | Phase 2 Clinical | Keymed Biosciences Co Ltd | Nose Diseases; Nasal Polyps; Asthma; Sinusitis; Pulmonary Disease, Chronic Obstructive; Dermatitis, Atopic | 詳細 |
| PF-06342674 | RN-168; PF-6342674; PF-06342674; ZB-168 | Phase 1 Clinical | Pfizer Inc | Diabetes Mellitus, Type 1; Multiple Sclerosis | 詳細 |
| HBM-9378 | SKB378; HBM-9378 | Phase 1 Clinical | Harbour Biomed, Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | Asthma | 詳細 |
| HB-0056 | HB-0056; HB0056 | Phase 1 Clinical | Shanghai Huaota Biopharmaceutical Co Ltd | Asthma | 詳細 |
| IBI-3002 | IBI3002; IBI-3002 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Asthma | 詳細 |
| GB-0895 | GB-0895 | Phase 1 Clinical | Immune System Diseases; Asthma | 詳細 | |
| STSA-1201 | STSA-1201; STSA1201 | Phase 1 Clinical | Asthma | 詳細 | |
| LQ043H | LQ043H | Phase 1 Clinical | Shanghai Novamab Biopharmaceuticals Co Ltd | Asthma | 詳細 |
| GR2002 | GR2002 | Phase 1 Clinical | Genrix (Shanghai) Biopharmaceutical Co Ltd | Nasal Polyps; Asthma; Sinusitis; Dermatitis, Atopic | 詳細 |
| QX-008N | QX008N; QX-008N | Phase 1 Clinical | Qyuns Therapeutics Co Ltd | Asthma; Pulmonary Disease, Chronic Obstructive | 詳細 |
| BD-9 | BD-9 | Biolojic Design Inc | 詳細 |
| 英語名 | 研究コード | 研究開発ステージ | 会社 | オリジナル製品名 | 最初に承認をした国 | 最初の適応症 | 最初に承認を受けた会社 | 承認された日付 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|---|---|---|---|---|
| Tezepelumab | AMG-157; MEDI-9929 | Approved | Amgen Inc | Tezspire | United States | Asthma | Astrazeneca Ab | 2021-12-17 | Eosinophilic Esophagitis; Hypersensitivity; Dermatitis, Atopic; Hypersensitivity, Immediate; Bronchial Diseases; Pulmonary Disease, Chronic Obstructive; Respiratory Hypersensitivity; Sinusitis; Asthma; Granulomatosis with Polyangiitis; Lung Diseases; Immune System Diseases; Chronic Urticaria; Respiratory Tract Diseases; Nasal Polyps; Anaphylaxis; Carcinoma; Lung Diseases, Obstructive | 詳細 |

お問い合わせ
グローバル:+1 800-810-0816(Toll Free)
メールアドレス
order.jp@acrobiosystems.com
アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8



